Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Accumulated Expenses (2016 - 2025)

OptimizeRx's Accumulated Expenses history spans 16 years, with the latest figure at $10.2 million for Q3 2025.

  • For Q3 2025, Accumulated Expenses rose 83.52% year-over-year to $10.2 million; the TTM value through Sep 2025 reached $10.2 million, up 83.52%, while the annual FY2024 figure was $8.5 million, 10.12% up from the prior year.
  • Accumulated Expenses for Q3 2025 was $10.2 million at OptimizeRx, down from $12.5 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $12.5 million in Q2 2025 and bottomed at $750130.0 in Q4 2022.
  • The 5-year median for Accumulated Expenses is $2.9 million (2021), against an average of $4.6 million.
  • The largest annual shift saw Accumulated Expenses plummeted 74.16% in 2022 before it surged 927.29% in 2023.
  • A 5-year view of Accumulated Expenses shows it stood at $2.9 million in 2021, then tumbled by 74.16% to $750130.0 in 2022, then soared by 927.29% to $7.7 million in 2023, then increased by 10.12% to $8.5 million in 2024, then increased by 20.17% to $10.2 million in 2025.
  • Per Business Quant, the three most recent readings for OPRX's Accumulated Expenses are $10.2 million (Q3 2025), $12.5 million (Q2 2025), and $9.3 million (Q1 2025).